CN111670199B - 用于治疗人癌瘤的单克隆抗体neo-201 - Google Patents

用于治疗人癌瘤的单克隆抗体neo-201 Download PDF

Info

Publication number
CN111670199B
CN111670199B CN201880085205.0A CN201880085205A CN111670199B CN 111670199 B CN111670199 B CN 111670199B CN 201880085205 A CN201880085205 A CN 201880085205A CN 111670199 B CN111670199 B CN 111670199B
Authority
CN
China
Prior art keywords
neo
ser
cancer
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880085205.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111670199A (zh
Inventor
P·M·阿兰
K·Y·曾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Precision Biological Products Co ltd
Original Assignee
Precision Biological Products Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precision Biological Products Co ltd filed Critical Precision Biological Products Co ltd
Priority to CN202510631395.3A priority Critical patent/CN120860200A/zh
Priority to CN202411004231.XA priority patent/CN119587690A/zh
Publication of CN111670199A publication Critical patent/CN111670199A/zh
Application granted granted Critical
Publication of CN111670199B publication Critical patent/CN111670199B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201880085205.0A 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201 Active CN111670199B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202510631395.3A CN120860200A (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201
CN202411004231.XA CN119587690A (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762581380P 2017-11-03 2017-11-03
US62/581,380 2017-11-03
US201762592778P 2017-11-30 2017-11-30
US62/592,778 2017-11-30
PCT/US2018/059039 WO2019090134A1 (en) 2017-11-03 2018-11-02 Monoclonal antibody neo-201 for the treatment of human carcinomas

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202510631395.3A Division CN120860200A (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201
CN202411004231.XA Division CN119587690A (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201

Publications (2)

Publication Number Publication Date
CN111670199A CN111670199A (zh) 2020-09-15
CN111670199B true CN111670199B (zh) 2025-06-17

Family

ID=66332711

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201880085205.0A Active CN111670199B (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201
CN202411004231.XA Pending CN119587690A (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201
CN202510631395.3A Pending CN120860200A (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202411004231.XA Pending CN119587690A (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201
CN202510631395.3A Pending CN120860200A (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201

Country Status (7)

Country Link
US (2) US11767367B2 (enExample)
EP (1) EP3735423A4 (enExample)
JP (3) JP7437307B2 (enExample)
CN (3) CN111670199B (enExample)
AU (2) AU2018360045B2 (enExample)
CA (1) CA3083467A1 (enExample)
WO (1) WO2019090134A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020016374A2 (pt) 2018-02-13 2020-12-15 Precision Biologics, Inc. Métodos e composições para direcionar células treg
CN115678854A (zh) * 2021-07-29 2023-02-03 上海中医药大学 一种基因工程细胞及其制备方法和应用
CN119053622A (zh) * 2022-04-12 2024-11-29 盛禾(中国)生物制药有限公司 一种抗ceacam5和ceacam6抗体及其应用
CN116699135B (zh) * 2022-04-29 2025-11-07 中国医学科学院肿瘤医院 癌症免疫治疗靶标和诊断、预后预测生物标志物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831620A (zh) * 2017-05-26 2020-02-21 埃特彼塞斯公司 包含il-15超激动剂的联合免疫疗法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189268A1 (en) * 2010-06-22 2013-07-25 Precision Biologics, Inc. Colon and pancreas cancer specific antigens and antibodies
US9938344B2 (en) * 2012-12-28 2018-04-10 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
PL3160498T3 (pl) * 2014-06-30 2022-02-21 Altor Bioscience Corporation Cząsteczki na bazie IL-15 i sposoby ich zastosowania

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831620A (zh) * 2017-05-26 2020-02-21 埃特彼塞斯公司 包含il-15超激动剂的联合免疫疗法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Identification of target and cytotoxicity of novel monoclonal antibody NEO-201 in ovarian and uterine cancer subtypes;M.K. Neuman等;Gynecologic oncology;第141卷;1-6 *
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.;Philip M Arlen 等;Frontiers in immunology;第8卷;1-14 *

Also Published As

Publication number Publication date
AU2018360045A1 (en) 2020-05-21
EP3735423A1 (en) 2020-11-11
CA3083467A1 (en) 2019-05-09
US11767367B2 (en) 2023-09-26
EP3735423A4 (en) 2021-02-24
JP2025148435A (ja) 2025-10-07
CN111670199A (zh) 2020-09-15
WO2019090134A1 (en) 2019-05-09
US20200362053A1 (en) 2020-11-19
CN120860200A (zh) 2025-10-31
JP7437307B2 (ja) 2024-02-22
AU2018360045B2 (en) 2025-04-17
US20240101702A1 (en) 2024-03-28
JP7712338B2 (ja) 2025-07-23
AU2025205420A1 (en) 2025-07-31
JP2021502416A (ja) 2021-01-28
JP2024010054A (ja) 2024-01-23
CN119587690A (zh) 2025-03-11

Similar Documents

Publication Publication Date Title
CN113347994B (zh) 使用her3抗原结合分子治疗和预防癌症
CN112513095B (zh) Her3抗原结合分子
KR101732201B1 (ko) 혈액 종양 치료를 목적으로 하는 항ＩＬ－３Ｒα 항체
JP7712338B2 (ja) ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
US20240400714A1 (en) Methods and compositions for targeting treg cells
CN111094982A (zh) 用于治疗和诊断癌症的tim-3拮抗剂
Fantini et al. Preclinical characterization of a novel monoclonal antibody NEO-201 for the treatment of human carcinomas
JP7219207B2 (ja) 腫瘍関連マクロファージを標的化する抗体及びその使用
EP4490273A1 (en) New chimeric antigen receptor (car) cells and medical uses thereof
CN118234748A (zh) 用于治疗血液恶性肿瘤的方法和组合物
HK40052624B (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK40052624A (en) Treatment and prevention of cancer using her3 antigen-binding molecules

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant